TECTONIC THERAPEUTIC, INC. Other Comprehensive Income (Loss), Tax
TECTONIC THERAPEUTIC, INC. (TECX) reported Other Comprehensive Income (Loss), Tax of $22.29 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossTax · last filed 2026-08-06
- TECTONIC THERAPEUTIC, INC. other comprehensive income (loss), tax for the quarter ending 2026-06-30 was $22.29M, a 11.23% increase year-over-year.
- TECTONIC THERAPEUTIC, INC. other comprehensive income (loss), tax for the quarter ending 2026-03-31 was $25.20M, a 58.39% increase year-over-year.
- TECTONIC THERAPEUTIC, INC. other comprehensive income (loss), tax for the quarter ending 2025-12-31 was $19.25M, a 56.51% increase year-over-year.
- TECTONIC THERAPEUTIC, INC. other comprehensive income (loss), tax for the quarter ending 2025-09-30 was $19.06M, a 7.49% increase year-over-year.
- TECTONIC THERAPEUTIC, INC. other comprehensive income (loss), tax for fiscal 2025 was $74.26M, a 28.09% increase from fiscal 2024.
- TECTONIC THERAPEUTIC, INC. other comprehensive income (loss), tax for fiscal 2024 was $57.97M, a 35.34% increase from fiscal 2023.
- TECTONIC THERAPEUTIC, INC. other comprehensive income (loss), tax for fiscal 2023 was $42.83M.
| Period end | Other Comprehensive Income (Loss), Tax 3 month | Other Comprehensive Income (Loss), Tax 6 month | Other Comprehensive Income (Loss), Tax 9 month | Other Comprehensive Income (Loss), Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.29M 10-Q · filed 2026-08-06 | $47.49M 10-Q · filed 2026-08-06 | $66.74M derived: sum of 3 quarters · filed 2026-08-06 | $85.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $25.20M 10-Q · filed 2026-05-07 | $44.45M derived: sum of 2 quarters · filed 2026-05-07 | $63.51M derived: sum of 3 quarters · filed 2026-05-07 | $83.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $19.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $38.31M derived: sum of 2 quarters · filed 2026-02-26 | $58.34M derived: sum of 3 quarters · filed 2026-08-06 | $74.26M 10-K · filed 2026-02-26 |
| 2025-09-30 | $19.06M 10-Q · filed 2025-11-06 | $39.10M derived: sum of 2 quarters · filed 2026-08-06 | $55.01M 10-Q · filed 2025-11-06 | $67.31M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $20.04M 10-Q · filed 2026-08-06 | $35.95M 10-Q · filed 2026-08-06 | $48.25M derived: sum of 3 quarters · filed 2026-08-06 | $65.98M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $15.91M 10-Q · filed 2026-05-07 | $28.21M derived: sum of 2 quarters · filed 2026-05-07 | $45.94M derived: sum of 3 quarters · filed 2026-05-07 | $58.62M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $12.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $30.03M derived: sum of 2 quarters · filed 2026-02-26 | $42.71M derived: sum of 3 quarters · filed 2026-02-26 | $57.97M 10-K · filed 2026-02-26 |
| 2024-09-30 | $17.73M 10-Q · filed 2025-11-06 | $30.41M derived: sum of 2 quarters · filed 2025-11-06 | $45.67M 10-Q · filed 2025-11-06 | $53.56M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $12.68M 10-Q · filed 2025-08-07 | $27.94M 10-Q · filed 2025-08-07 | $35.83M derived: sum of 3 quarters · filed 2025-08-07 | $45.88M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $15.27M 10-Q · filed 2025-05-08 | $23.15M derived: sum of 2 quarters · filed 2025-05-08 | $33.20M derived: sum of 3 quarters · filed 2025-05-08 | $43.66M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $7.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $17.93M derived: sum of 2 quarters · filed 2025-03-20 | $28.39M derived: sum of 3 quarters · filed 2025-03-20 | $42.83M 10-K · filed 2025-03-20 |
| 2023-09-30 | $10.05M 10-Q · filed 2024-11-12 | $20.51M derived: sum of 2 quarters · filed 2024-11-12 | $34.95M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $10.46M 10-Q · filed 2024-08-14 | $24.90M 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |